中等度から重度の化膿性汗腺炎の成人患者におけるセクキヌムAbの治療パターンに関する現実世界の集団データを収集するための長期観察的、前向き、多施設研究。 (ANIMA)
中等度から重度の化膿性汗腺炎(HS)の成人患者におけるセクキナムAbの治療パターンに関するデータを現実世界の人口で収集するための長期観察、前向き、多施設研究(ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
調査の概要
詳細な説明
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Aachen、ドイツ、52064
- Novartis Investigative Site
-
Ahaus、ドイツ、48683
- Novartis Investigative Site
-
Annaberg-Buchholz、ドイツ、09456
- Novartis Investigative Site
-
Bad Steben、ドイツ、95138
- Novartis Investigative Site
-
Baden-Baden、ドイツ、76530
- Novartis Investigative Site
-
Berlin、ドイツ、12159
- Novartis Investigative Site
-
Berlin、ドイツ、13595
- Novartis Investigative Site
-
Bielefeld、ドイツ、33647
- Novartis Investigative Site
-
Bochum、ドイツ、44791
- Novartis Investigative Site
-
Bonn、ドイツ、53105
- Novartis Investigative Site
-
Brandenburg、ドイツ、14776
- Novartis Investigative Site
-
Bremen、ドイツ、28359
- Novartis Investigative Site
-
Buxtehude、ドイツ、21614
- Novartis Investigative Site
-
Bückeburg、ドイツ、31675
- Novartis Investigative Site
-
Chemnitz、ドイツ、09117
- Novartis Investigative Site
-
Chemnitz、ドイツ、09113
- Novartis Investigative Site
-
Cologne、ドイツ、51065
- Novartis Investigative Site
-
Delitzsch、ドイツ、04509
- Novartis Investigative Site
-
Dessau、ドイツ、06847
- Novartis Investigative Site
-
Dorsten、ドイツ、46282
- Novartis Investigative Site
-
Dortmund、ドイツ、44137
- Novartis Investigative Site
-
Dresden、ドイツ、01309
- Novartis Investigative Site
-
Düren、ドイツ、52349
- Novartis Investigative Site
-
Emsdetten、ドイツ、48282
- Novartis Investigative Site
-
Erlangen、ドイツ、91054
- Novartis Investigative Site
-
Falkenberg、ドイツ、04895
- Novartis Investigative Site
-
Falkensee、ドイツ、14612
- Novartis Investigative Site
-
Freising、ドイツ、85354
- Novartis Investigative Site
-
Geilenkirchen、ドイツ、52511
- Novartis Investigative Site
-
Gera、ドイツ、07548
- Novartis Investigative Site
-
Gernsbach、ドイツ、76593
- Novartis Investigative Site
-
Gladbeck、ドイツ、45964
- Novartis Investigative Site
-
Großenhain、ドイツ、01558
- Novartis Investigative Site
-
Hamburg、ドイツ、20246
- Novartis Investigative Site
-
Hamburg、ドイツ、22143
- Novartis Investigative Site
-
Hanover、ドイツ、30159
- Novartis Investigative Site
-
Haslach im Kinzigtal、ドイツ、77716
- Novartis Investigative Site
-
Hofgeismar、ドイツ、34369
- Novartis Investigative Site
-
Jena、ドイツ、07743
- Novartis Investigative Site
-
Jülich、ドイツ、52428
- Novartis Investigative Site
-
Karlsruhe、ドイツ、76133
- Novartis Investigative Site
-
Kempen、ドイツ、47906
- Novartis Investigative Site
-
Lübeck、ドイツ、23538
- Novartis Investigative Site
-
Magdeburg、ドイツ、39120
- Novartis Investigative Site
-
Magdeburg、ドイツ、39104
- Novartis Investigative Site
-
Mainz、ドイツ、55116
- Novartis Investigative Site
-
Marburg、ドイツ、35043
- Novartis Investigative Site
-
Minden、ドイツ、32429
- Novartis Investigative Site
-
Mönchengladbach、ドイツ、41063
- Novartis Investigative Site
-
Neu Wulmstorf、ドイツ、21629
- Novartis Investigative Site
-
Nuremberg、ドイツ、90419
- Novartis Investigative Site
-
Oberasbach、ドイツ、90522
- Novartis Investigative Site
-
Oelde、ドイツ、59302
- Novartis Investigative Site
-
Peitz、ドイツ、03185
- Novartis Investigative Site
-
Potsdam、ドイツ、14469
- Novartis Investigative Site
-
Remscheid、ドイツ、42897
- Novartis Investigative Site
-
Selters、ドイツ、56242
- Novartis Investigative Site
-
Simmern、ドイツ、55469
- Novartis Investigative Site
-
Soest、ドイツ、59494
- Novartis Investigative Site
-
Stolberg、ドイツ、52222
- Novartis Investigative Site
-
Unna、ドイツ、59423
- Novartis Investigative Site
-
Wittlich、ドイツ、54316
- Novartis Investigative Site
-
Wuppertal、ドイツ、42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、ドイツ、79068
- Novartis Investigative Site
-
Rheinstetten、Baden-Wurttemberg、ドイツ、76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt、Bavaria、ドイツ、97437
- Novartis Investigative Site
-
Kulmbach、Bavaria、ドイツ、95326
- Novartis Investigative Site
-
Lauf an der Pegnitz、Bavaria、ドイツ、91207
- Novartis Investigative Site
-
Nuremberg、Bavaria、ドイツ、90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal、Brandenburg、ドイツ、16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg、Free and Hanseatic City of Hamburg、ドイツ、22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen、Lower Saxony、ドイツ、49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen、Mecklenburg-Vorpommern、ドイツ、18528
- Novartis Investigative Site
-
Kröpelin、Mecklenburg-Vorpommern、ドイツ、18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld、North Rhine-Westphalia、ドイツ、47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz、Rhineland-Palatinate、ドイツ、55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- Novartis Investigative Site
-
Leipzig、Saxony、ドイツ、04207
- Novartis Investigative Site
-
Leipzig、Saxony、ドイツ、04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg、Saxony-Anhalt、ドイツ、06886
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
説明
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients receiving up-titration
時間枠:Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
時間枠:Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
時間枠:Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
時間枠:Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
時間枠:Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
時間枠:Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
時間枠:Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
時間枠:Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
時間枠:Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
時間枠:Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
時間枠:Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
時間枠:Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。